Why Clene Inc.’s (CLNN) Stock Is Down 5.81%
As of Monday, September 28, Clene Inc.’s CLNN share price has dipped by 5.81%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company’s lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Commentary & Analysis
Why Clene Inc.’s (CLNN) Stock Is Down 5.02%
As of Wednesday, September 23, Clene Inc.’s CLNN share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Clene Inc.’s (CLNN) Stock Is Up 5.66%
As of Friday, September 18, Clene Inc.’s CLNN share price has surged by 5.66%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Clene Inc.’s (CLNN) Stock Is Down 6.26%
As of Friday, September 04, Clene Inc.’s CLNN share price has dipped by 6.26%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Clene Inc.’s (CLNN) Stock Is Down 5.59%
As of Friday, August 28, Clene Inc.’s CLNN share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CLNN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $54.9 | $242.6 | 16% |
|
| Shares Out (Mil) | 12.4 | 54.0 | 24% |
|
| Institutional Ownership | 66.6% | 93.1% | 41% |
|
| Float (Mil) | 10.7 | 41.4 | 20% |
|
| Beta | 0.95 | 0.95 | 57% |
|
| Avg Daily Volume (000s) | 87 | 633 | 34% |
|
| Price Change (52-week) |
(59.0%) | 50.0% | 15% |
|
| Growth | CLNN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.0% | 12.5% | 18% |
|
| Net Income (5yr) | (6.3%) | (10.1%) | 33% |
|
| EPS (5yr) | 34.5% | 15.8% | 85 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.475) | ($2.620) | ($2.440) | |
| Month Ago EPS | ($0.475) | ($2.620) | ($2.440) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.280) | ($1.405) | ($1.790) | |
| Year/Year Chg | (56.2%) | (1.3%) | (209.4%) | |
| Financials | CLNN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $37 | 0% |
|
| Net Income (TTM) (Mil) | ($40) | ($44) | 18% |
|
| EPS (TTM) | ($3.504) | ($1.600) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($34) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $21 | $4 | 33% |
|
| Enterprise Value (Q1) (Mil) | $69 | $177 | 18% |
|
| Valuation | CLNN | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.33 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CLNN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 70.1% | 67.3% | 81% |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (175.0%) | (47.6%) | 2% |
|
| ROE | 237.2% | (54.9%) | 98% |
|
| Liabilities to Assets | 207.5% | 29.3% | 99% |
|
| F-Score | 2 | 3 | 7% |
|
Clene Inc. did not pass any screens on 10/9/2026.
